News ArchivesRead News
Breakthrough technology for testing Alzheimer’s and Parkinson’s drugs
Thursday February 18, 2010
news@Northwestern - In a breakthrough development for early drug research, Northeastern University scientists are now able to test, in real time, the impact of new drugs being developed to treat neurodegenerative diseases like Alzheimer’s and Parkinson’s.
A patented new imaging technology developed by Northeastern’s Center for Translational NeuroImaging (CTNI) enables researchers to produce highly accurate data without resorting to traditional preclinical testing methods. Those methods involve euthanizing laboratory animals at different stages of the study to assess disease progression and the effectiveness of the drug.
“Animal imaging is crucial in early drug discovery, but the use of anesthesia creates an artificial situation that can mask true drug activity,” said Craig Ferris, CTNI director and professor of psychology and pharmaceutical sciences. “Studying awake animals leads to improved drug safety evaluations and data accuracy.”
Ferris noted the testing they are now able to perform at CTNI maximizes accuracy and leads to improved drug development processes for pharmaceutical and biotechnology companies that are working to treat central nervous system diseases, including Alzheimer’s and Parkinson’s diseases.
The center’s imaging-based preclinical testing is performed under the aegis of a new business venture, called Ekam Imaging, Inc., founded by a team that includes Ferris and Graham Jones, professor and chair of the department of chemistry and chemical biology at Northeastern.
The technology has spawned eight patents focused on the imaging of animals and a new method for tagging drugs using microwave-mediated organic synthesis technology. This procedure allows injected compounds to be more accurately tracked and evaluated for efficacy.
Additionally, the center uses advanced data-analysis techniques, including three-dimensional brain “atlases” used for data visualization, and imaging models of various disease conditions.
“The advantages of our technology give researchers the ability to provide information and analysis to drug companies that enable them to make more informed go/no-go decisions on their drug development programs,” added Ferris. “It will help reduce the time to market for new therapeutics and lower the overall cost of drug development.”
Recent NewsOct 18 - Fighting Parkinson's disease through dance
Oct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show